Get startedLog in
    Picture of Amgen logo

    AMGN — Amgen News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Amgen's Repatha Cuts Risk Of First Major Cardiovascular Event By 31% In High-Risk Patients

    Picture of Amgen logoAmgen
    28/03/2026 20:45
    March 28 (Reuters) - Amgen Inc AMGN.O:

AMGEN: PHASE 3 VESALIUS-CV CLINICAL TRIAL SHOWED REPATHA REDUCED RISKS OF HEART ATTACK, CORONARY HEART DISEASE  DEATH, ISCHEMIC STROKE

AMGEN: REPATHA CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENT BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Source text: [ID:]

Further company coverage: AMGN.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Amgen

    See all news